Artificial Intelligence Applications in Glioma With 1p/19q Co-Deletion: A Systematic Review

被引:5
|
作者
Zhang, Simin [2 ]
Yin, Lijuan [3 ]
Ma, Lu [4 ]
Sun, Huaiqiang [1 ,2 ]
机构
[1] Sichuan Univ, Huaxi MR Res Ctr HMRRC, Dept Radiol, West China Hosp, Chengdu 610041, Peoples R China
[2] Sichuan Univ, Huaxi MR Res Ctr HMRRC, Dept Radiol, West China Hosp, Chengdu, Peoples R China
[3] Sichuan Univ, Dept Pathol, West China Hosp, Chengdu, Peoples R China
[4] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
artificial intelligence; machine learning; deep learning; 1p; 19q co-deletion; magnetic resonance imaging; glioma; CENTRAL-NERVOUS-SYSTEM; LOWER-GRADE GLIOMAS; CLASSIFICATION; GLIOBLASTOMA; RESECTION; IMPACT; TUMORS; IDH;
D O I
10.1002/jmri.28737
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
As an important genomic marker for oligodendrogliomas, early determination of 1p/19q co-deletion status is critical for guiding therapy and predicting prognosis in patients with glioma. The purpose of this study is to systematically review the literature concerning the magnetic resonance imaging (MRI) with artificial intelligence (AI) methods for predicting 1p/19q co-deletion status in glioma. PubMed, Scopus, Embase, and IEEE Xplore were searched in accordance with the Preferred Reporting Items for systematic reviews and meta-analyses guidelines. Methodological quality of studies was assessed according to the Quality Assessment of Diagnostic Accuracy Studies-2. Finally, 28 studies were included in the quantitative analysis. Diagnostic test accuracy reached an area under the ROC curve of 0.71-0.98 were reported in 24 studies. The remaining four studies with no available AUC provided an accuracy of 0.75-0. 89. The included studies varied widely in terms of imaging sequences, input features, and modeling methods. The current review highlighted that integrating MRI with AI technology is a potential tool for determination 1p/19q status pre-operatively and noninvasively, which can possibly help clinical decision-making. However, the reliability and feasibility of this approach still need to be further validated and improved in a real clinical setting. Evidence Level2. Technical Efficacy2.
引用
收藏
页码:1338 / 1352
页数:15
相关论文
共 50 条
  • [21] Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing 1p/19q Co-Deletion Analysis of Gliomas
    Dubbink, Hendrikus J.
    Atmodimedjo, Peggy N.
    van Marion, Ronald
    Krol, Niels M. G.
    Riegman, Peter H. J.
    Kros, Johan M.
    van den Bent, Martin J.
    Dinjens, Winand N. M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (05) : 775 - 786
  • [22] Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas
    Zhang, Lu
    Fritah, Sabrina
    Nazarov, Petr V.
    Kaoma, Tony
    Van Dyck, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
  • [23] Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
    van den Bent, Martin J.
    Klein, Martin
    Smits, Marion
    Reijneveld, Jaap C.
    French, Pim J.
    Clement, Paul
    de Vos, Filip Y. F.
    Wick, Antje
    Mulholland, Paul J.
    Taphoorn, Martin J. B.
    Lewis, Joanne
    Weller, Michael
    Chinot, Olivier L.
    Kros, Johan M.
    de Heer, Iris
    Verschuere, Tina
    Coens, Corneel
    Golfinopoulos, Vassilis
    Gorlia, Thierry
    Idbaih, Ahmed
    LANCET ONCOLOGY, 2018, 19 (09) : 1170 - 1179
  • [24] Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with IDH mutations and 1p/19q co-deletion
    Zhao, Xin-Wei
    Zhan, Yun-Bo
    Bao, Jian-Ji
    Zhou, Jin-Qiao
    Zhang, Feng-Jiang
    Bin, Yu
    Bai, Ya-Hui
    Wang, Yan-Min
    Zhang, Zhen-Yu
    Liu, Xian-Zhi
    ONCOTARGET, 2017, 8 (70) : 115657 - 115666
  • [25] 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas
    Zhang, Yanyu
    Xie, Yuan
    He, Liqun
    Tang, Jiefu
    He, Qiyuan
    Cao, Qingze
    Cui, Langjun
    Guo, Wei
    Hua, Kai
    Dimberg, Anna
    Wang, Liang
    Zhang, Lei
    CELLULAR ONCOLOGY, 2021, 44 (01) : 193 - 204
  • [26] A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas
    Yogananda, Chandan Ganesh Bangalore
    Shah, Bhavya R.
    Yu, Frank F.
    Pinho, Marco C.
    Nalawade, Sahil S.
    Murugesan, Gowtham K.
    Wagner, Benjamin C.
    Mickey, Bruce
    Patel, Toral R.
    Fei, Baowei
    Madhuranthakam, Ananth J.
    Maldjian, Joseph A.
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (SUPP 4) : 42 - 48
  • [27] Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients
    Wang, Kai
    Wang, Yinyan
    Fan, Xing
    Li, Yanong
    Liu, Xing
    Wang, Jiangfei
    Ai, Lin
    Dai, Jianping
    Jiang, Tao
    JOURNAL OF NEURO-ONCOLOGY, 2018, 136 (03) : 523 - 531
  • [28] Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion
    Gladitz, Josef
    Klink, Barbara
    Seifert, Michael
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 49
  • [29] Real-time Quantitative Polymerase Chain Reaction Assay for Detecting 1p and 19q Codeletion in Glioma
    Niem Van Thanh Vo
    Diem Dinh-Kieu Truong
    Phan Thi Xinh
    Vu, Hoang Anh
    BIOMEDICAL AND BIOTECHNOLOGY RESEARCH JOURNAL, 2023, 7 (04): : 563 - 568
  • [30] Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas
    Han, Yuqi
    Xie, Zhen
    Zang, Yali
    Zhang, Shuaitong
    Gu, Dongsheng
    Zhou, Mu
    Gevaert, Olivier
    Wei, Jingwei
    Li, Chao
    Chen, Hongyan
    Du, Jiang
    Liu, Zhenyu
    Dong, Di
    Tian, Jie
    Zhou, Dabiao
    JOURNAL OF NEURO-ONCOLOGY, 2018, 140 (02) : 297 - 306